This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571) COVID-19 in an Elderly Population (15) COVID-19 Vaccination (146) Hygiene and Infection Prevention (317) Psychological, -behavioural, -social, and/or -cultural Experiments and Interventions (52) Behavioural Surveillance for Public Health (229)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/52643, first published .
The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study

The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study

The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study

Authors of this article:

Paul Williams1, 2 Author Orcid Image ;   Timothy A Herring3 Author Orcid Image ;   Renata T C Yokota4 Author Orcid Image ;   Tiago Maia5 Author Orcid Image ;   Sudhir Venkatesan6 Author Orcid Image ;   James C Marcus7 Author Orcid Image ;   Gabriella Settergren8 Author Orcid Image ;   Sofie Arnetorp9 Author Orcid Image ;   Andrew Lloyd10 Author Orcid Image ;   Johan L Severens11 Author Orcid Image ;   James W Varni12 Author Orcid Image ;   Sharon Dixon13 Author Orcid Image ;   Lweendo Hamusankwa14 Author Orcid Image ;   Philip A Powell15, 16 Author Orcid Image ;   Sylvia Taylor17 Author Orcid Image ;   John E Ware Jr18 Author Orcid Image ;   Marieke Krol19 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Paul Williams   1, 2 * , MPH ;   Timothy A Herring   3 * , MPH ;   Renata T C Yokota   4 , MSc, MPH, PhD ;   Tiago Maia   5 , MPH ;   Sudhir Venkatesan   6 , MPH, PhD ;   James C Marcus   7 , PhD ;   Gabriella Settergren   8 , MSc ;   Sofie Arnetorp   9 , MSc ;   Andrew Lloyd   10 , DPhil ;   Johan L Severens   11 , PhD ;   James W Varni   12 , PhD ;   Sharon Dixon   13 ;   Lweendo Hamusankwa   14 , BSc ;   Philip A Powell   15, 16 , PhD ;   Sylvia Taylor   17 , MBA, MPH, PhD ;   John E Ware Jr   18 , PhD ;   Marieke Krol   19 , PhD

1 Global Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

2 Patient Centered Solutions, IQVIA, Courbevoie, France

3 Medical Evidence, Epidemiology, Vaccine & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, United States

4 P95, Epidemiology & Pharmacovigilance, Leuven, Belgium

5 Patient Centered Solutions, IQVIA, Porto Salvo, Portugal

6 BPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom

7 Patient Centered Solutions, IQVIA, Washington, DC, United States

8 Global Evidence Portfolio Delivery, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

9 Health Economic & Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

10 Acaster Lloyd Consulting Ltd, London, United Kingdom

11 Severens HTA Consultancy, Venray, Netherlands

12 Texas A&M University, College Station, TX, United States

13 Patient representative, Sulphur Springs, TX, United States

14 Patient representative, London, United Kingdom

15 Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, United Kingdom

16 Philip A Powell Consulting, Sheffield, United Kingdom

17 Medical Evidence, Vaccine & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom

18 John Ware Research Group, Watertown, ME, United States

19 Patient Centered Solutions, IQVIA, Amsterdam, Netherlands

*these authors contributed equally

Corresponding Author: